Os Therapies Incorporated

OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes

OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor

OS Therapies Appoints Craig Eagle, MD as Strategic Advisor

OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors

OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update